首頁 > 市場調查報告書 > 醫療設備

透析設備

市場調查報告書

商品編碼

1347967

全球單採市場 - 2023-2030

Global Apheresis Market - 2023-2030

出版日期: 2023年09月11日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球單採市場在 2022 年達到 18 億美元，預計到 2030 年將達到 50 億美元，2023-2030 年預測期間年複合成長率為 8.4%。

單採術是一種醫療技術醫療程序，涉及分離、提取和收集人體血液的特定成分。設備推出數量的增加和血液疾病的增加預計將推動市場成長。

北美地區預計將佔據重要的市場佔有率。血漿置換領域佔有重要的市場佔有率。設備技術進步的增加及其優勢使該領域處於重要地位。

根據 DataM Intelligence，Apheresis 市場研究分析提供了包含定量和定性數據的市場深入展望。它根據市場細分對全球市場進行了展望和預測。

動力學

設備發布數量的增加預計將推動市場成長

設備發布數量的增加預計將推動市場成長。例如，2022 年 9 月 20 日，醫療技術公司 Terumo Blood and Cell Technologies (Terumo BCT) 推出了 Quantum Flex Cell Expansion System，這是一個生物反應器平台，支持細胞和基因治療的工藝開發到商業製造。資本利得稅）部門。

此外，例如，Terumo Blood and Cell Technologies 於 2023 年 8 月 1 日推出了 Reveos 設備，可在單個離心循環中將血液處理成血小板，該設備已獲得美國食品和藥物管理局 (FDA) 的批准。因此，發布數量的增加預計將推動市場成長。

血液疾病的增加預計將推動市場成長

血液疾病的增加預計將推動市場成長。例如，根據 CDC 的數據，鐮狀細胞病影響著大約 100,000 名美國人。每 365 名黑人或非裔美國人新生兒中就有 1 名患有 SCD。每 16,300 名出生的西班牙裔美國人中大約就有 1 人患有此病。大約三分之一的黑人或非裔美國嬰兒出生時就患有鐮狀細胞性狀 (SCT)。

紅細胞交換用於治療或有時預防鐮狀細胞病的嚴重併發症，例如中風和急性胸部症候群。在紅細胞交換中，通過單採術去除患病或異常的紅細胞，然後用供體紅細胞替換。此外，美國癌症協會預計 2023 年美國白血病新發病例（各類）約為 59,610 例，死於白血病（各類）的人數為 23,710 例，急性髓系白血病 (AML) 新增病例為 20,380 例。白細胞去除術涉及從循環血液中去除患者的白細胞。因此，血液系統疾病的增加

與血漿分離術相關的高成本預計將阻礙市場成長

這些程序的高成本也是限制市場成長的一大因素。例如，每次血漿置換術的平均成本在 1,500 美元到 2,500 美元之間。單採術過程存在多種風險，其中最重要的風險是血液污染，這在手術過程中很常見。

血漿分離術的其他併發症也會影響市場成長。最常見的單採特異性反應是檸檬酸鹽抗凝引起的低鈣血症，雖然通常較輕微，但有可能嚴重傷害供體。重複的單採血液成分捐獻可能會對捐獻者產生長期不良影響，例如骨脫礦和白內障形成。因此，上述因素預計將阻礙市場成長。

Overview

Global Apheresis Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 5.0 billion by 2030, growing with a CAGR of 8.4% during the forecast period 2023-2030.

Apheresis is a medical technology medical procedure that involves the separation, extraction, and collection of specific components of a person's blood. The increased number of launches of the devices and an increase in hematological disorders are expected to drive market growth.

North America region is expected to hold a significant position in the market share. The plasmapheresis segment holds a significant market share. The increase in technological advancements in the Devices and their advantages are holding the segment in a significant position.

As per DataM Intelligence, Apheresis Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation.

Dynamics

Increased Number of Device Launches is Expected to Drive the Market Growth

An increased number of Device launches are expected to drive the market growth. For instance, on September 20, 2022, Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, launched its Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector.

Additionally, for instance, on August 1, 2023, Terumo Blood and Cell Technologies launched a Reveos device that processes blood into platelets in a single centrifugation cycle, which has been cleared by the US Food and Drug Administration (FDA). Thus, an increase in the number of launches is expected to drive the market growth.

Increase in Hematological Disorders is Expected to Drive Market Growth

An increase in hematological disorders is expected to drive market growth. For instance, according to the CDC, Sickle Cell Disease affects approximately 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African-American births. It occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).

Red blood cell exchange is used to treat or sometimes prevent serious complications of sickle cell disease, such as stroke and acute chest syndrome. In red blood cell exchange, diseased or abnormal red blood cells are removed by apheresis and then replaced by donor red blood cells. Additionally, The American Cancer Society's estimates for leukemia in the United States for 2023 are about 59,610 new cases of leukemia (all kinds) and 23,710 deaths from leukemia (all kinds), 20,380 new cases of acute myeloid leukemia (AML). Leukapheresis involves the removal of a patient's white blood cells from the circulating blood. Thus, the increase in hematological disorders

High costs Associated with Apheresis are Expected to Hamper the Market Growth

The high cost of these procedures is also a big factor restraining the growth of the market. For instance, the average cost of plasmapheresis ranges between $1,500 and $2,500 per procedure. Various risks are associated with the Apheresis procedure, and the crucial one is blood contamination, which is very common during the procedure.

Other complications with the apheresis can also affect the market growth. The most common apheresis-specific reaction is hypocalcemia due to citrate anticoagulation, which, while usually mild, has the potential to injure the donor severely. Repeated apheresis donation may produce adverse long-term effects in donors, such as bone demineralization and cataract formation. Thus, the above factors are expected to hamper the market growth.

Segment Analysis

The global apheresis market is segmented based on device, technology, procedure, and region.

Centrifugation Segment Holds a Significant Position in the Market Share

Centrifugal apheresis can be used to remove cellular components and is very efficient, achieving plasma extraction of nearly 80%. One of the benefits of centrifugal apheresis is that it requires lower blood flow rates and, therefore, can be performed using either peripheral or central venous access.

Most apheresis devices use centrifugation and require blood flow rates of 50-120 mL/min. Centrifugation takes advantage of the different specific gravities inherent to various blood products, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma. Thus, the advantages and efficiency of the centrfugation in seperating the whole blood components is holding a dominant position in the market share.

Geographical Penetration

North America region holds the largest market share in the global Apheresis market

North America holds a significant share of the global apheresis market. The increase in the number of blood transfusions and the increase in the demand for various blood components are holding the region's market growth. For instance, according to the American National Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S., nearly 5,000 units of platelets and 6,500 units of plasma are needed daily in the U.S., and about 16 million blood components are transfused each year in the U.S.

Additionally, according to the American Cancer Society, more than 1.9 million people are expected to be diagnosed with cancer in 2023. Many of them will need blood, sometimes daily, during their chemotherapy treatment. Thus, an increase in the demand for blood transfusions in the region is expected to hold the region in the dominant position.

Competitive Landscape

The global apheresis market is fragmented, with the presence of many local and international players. Fresenius SE & Co. KGaA, Cerus Corporation, Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, B. Braun, Melsungen, Kaneka Corporation, Terumo BCT, Inc., Kawasumi Laboratories Inc., and Nikkiso Europe GmbH, Baxter. are the leading Companies with a significant market share.

COVID-19 Impact Analysis

The COVID-19 epidemic is expected to benefit the development of the global apheresis business. Global healthcare systems were under pressure from the COVID-19 epidemic. Due to COVID-19, patients with severe infections had complications with their coagulation parameters, including platelet count, fibrinogen, D-dimer, prothrombin time (PT), and activated partial thromboplastin time (aPTT). As a result, plasma therapy was used extensively as a treatment. Patients who contracted the COVID-19 virus are treated with convalescent plasma (CP).

By Device

Apheresis Devices
Plasma Separators
Plasma Component Separators
Immunoadsorption Columns
Plasma Perfusion Columns
Hemoperfusion Columns
Apheresis Disposables

By Technology

Centrifugation
Intermittent Flow
Continuous Flow
Membrane Separation

By Procedure

Plasmapheresis
Plateletpheresis
Erythrocytapheresis
Leukapheresis
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Why Purchase the Report?

To visualize the global apheresis market segmentation based on device, technology, procedure, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of apheresis market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Device mapping available as excel consisting of key Devices of all the major players.

The global apheresis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Device
3.2. Snippet by Technology
3.3. Snippet by Procedure
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased number of device launches
  - 4.1.1.2. Increase in hematological disorders
- 4.1.2. Restraints
  - 4.1.2.1. High cost associated with apheresis
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Device

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 7.1.2. Market Attractiveness Index, By Device
7.2. Apheresis Devices *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Plasma Separators
7.4. Plasma Component Separators
7.5. Immunoadsorption Columns
7.6. Plasma Perfusion Columns
7.7. Hemoperfusion Columns
7.8. Apheresis Disposables

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Centrifugation *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intermittent Flow
8.4. Continuous Flow
8.5. Membrane Separation

9. By Procedure

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 9.1.2. Market Attractiveness Index, By Procedure
9.2. Plasmapheresis*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Plateletpheresis
9.4. Erythrocytapheresis
9.5. Leukapheresis
9.6. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Fresenius SE & Co. KGaA *
- 12.1.1. Company Overview
- 12.1.2. Device Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Cerus Corporation
12.3. Asahi Kasei Medical Co., Ltd.
12.4. Haemonetics Corporation
12.5. B. Braun Melsungen
12.6. Kaneka Corporation
12.7. Terumo BCT, Inc.
12.8. Kawasumi Laboratories Inc.
12.9. Nikkiso Europe GmbH
12.10. Baxter.

LIST NOT EXHAUSTIVE